Risk of third malignancies and death after a second malignancy in retinoblastoma survivors

Eur J Cancer. 2010 Jul;46(11):2052-8. doi: 10.1016/j.ejca.2010.03.029. Epub 2010 Apr 17.

Abstract

Retinoblastoma patients have a strongly increased risk of second malignancies, and survivors with a third or subsequent malignancy are increasingly observed. However, it has not been examined whether survivors who developed a second malignancy have a greater risk of a subsequent malignancy. On the basis of the Dutch retinoblastoma registry, the risk of a third malignancy was compared with cancer risk in the Dutch population. Cox model analysis with a time-dependent covariate was used to compare the subsequent malignancy risk and survival among patients with and without a second malignancy. Risk of a third malignancy was increased 8-fold compared with the general population. The hazard ratio (HR) of a third malignancy after a second malignancy was more than 7-fold increased compared to the risk of a second malignancy after retinoblastoma. Radiotherapy increased the risk 3-fold. A third malignancy was associated with worse survival compared with survival of patients only diagnosed with a second malignancy (HR=5.0). Survivors of retinoblastoma who already developed a second primary malignancy have an even higher risk of subsequent primary malignancies than retinoblastoma survivors without a second malignancy. Treating physicians and patients should be aware of this higher risk.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Neoplasms / mortality
  • Child
  • Child, Preschool
  • Epidemiologic Methods
  • Female
  • Humans
  • Infant
  • Male
  • Melanoma / mortality
  • Middle Aged
  • Neoplasms, Glandular and Epithelial / mortality
  • Neoplasms, Second Primary / mortality*
  • Netherlands / epidemiology
  • Retinal Neoplasms / mortality*
  • Retinoblastoma / mortality*
  • Skin Neoplasms / mortality
  • Soft Tissue Neoplasms / mortality
  • Survivors / statistics & numerical data*